Sarita Kapila
Stock Analyst at Morgan Stanley
(0.83)
# 3,874
Out of 4,476 analysts
54
Total ratings
45.5%
Success rate
-4.1%
Average return
Main Sectors:
Stocks Rated by Sarita Kapila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: AZN AstraZeneca PLC | Maintained: Buy | 16,500p | $14,456.00 | +14.14% | 10 | Jun 24, 2026 | |
| SNY Sanofi | Downgraded: Hold | $58 → $52 | $43.16 | +20.48% | 3 | May 1, 2026 | |
| SWX: ROP Roche Holding AG | Upgraded: Hold | CHF 295.00 | $340.60 | -13.39% | 10 | Apr 24, 2026 | |
| RHHBY Roche Holding AG | Maintained: Sell | $39 → $46 | $53.04 | -13.27% | 2 | Apr 7, 2026 | |
| LON: 0NZT UCB SA | Downgraded: Hold | €260.00 | $257.85 | +0.83% | 6 | Mar 6, 2026 | |
| LON: GSK GSK plc | Maintained: Sell | 1,600p → 1,700p | $2,015.00 | -15.63% | 8 | Mar 2, 2026 | |
| EPA: SAN Sanofi | Upgraded: Buy | €100.00 | $75.81 | +31.91% | 1 | Sep 8, 2025 | |
| STO: SOBI Swedish Orphan Biovitrum AB (publ) | Maintained: Hold | kr 253.10 → kr 257.88 | $479.00 | n/a | 2 | May 4, 2023 | |
| GRFS Grifols | Maintained: Buy | $16 → $18 | $7.16 | n/a | 2 | Feb 8, 2023 | |
| BME: GRF Grifols, S.A. | Maintained: Buy | €14.00 → €16.00 | $9.02 | n/a | 6 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $36 | $46.95 | n/a | 4 | Nov 16, 2022 |
AstraZeneca PLC
Jun 24, 2026
Maintained: Buy
Price Target: 16,500p
Current: $14,456.00
Upside: +14.14%
Sanofi
May 1, 2026
Downgraded: Hold
Price Target: $58 → $52
Current: $43.16
Upside: +20.48%
Roche Holding AG
Apr 24, 2026
Upgraded: Hold
Price Target: CHF 295.00
Current: $340.60
Upside: -13.39%
Roche Holding AG
Apr 7, 2026
Maintained: Sell
Price Target: $39 → $46
Current: $53.04
Upside: -13.27%
UCB SA
Mar 6, 2026
Downgraded: Hold
Price Target: €260.00
Current: $257.85
Upside: +0.83%
GSK plc
Mar 2, 2026
Maintained: Sell
Price Target: 1,600p → 1,700p
Current: $2,015.00
Upside: -15.63%
Sanofi
Sep 8, 2025
Upgraded: Buy
Price Target: €100.00
Current: $75.81
Upside: +31.91%
Swedish Orphan Biovitrum AB (publ)
May 4, 2023
Maintained: Hold
Price Target: kr 253.10 → kr 257.88
Current: $479.00
Upside: n/a
Grifols
Feb 8, 2023
Maintained: Buy
Price Target: $16 → $18
Current: $7.16
Upside: n/a
Grifols, S.A.
Feb 8, 2023
Maintained: Buy
Price Target: €14.00 → €16.00
Current: $9.02
Upside: n/a
Nov 16, 2022
Downgraded: Hold
Price Target: $36
Current: $46.95
Upside: n/a